La Jolla Pharma Gets FDA Approval for Blood Pressure Drug

 

Last week, La Jolla Pharmaceutical Company ( LJPC) received FDA approval for their low blood pressure injectible Giapreza

The intravenous injectible is used to raise blood pressure in adults with certain symptoms like sepsis, shock, and hypertension, but can also cause dangerous blood clots. The agency warns that use of this drug should be in conjunction with prophylactic treatments. 

In a 321 patient clinical trial Giapreza raised blood pressure against placebo tests, and received a 'Priority Review' from the FDA, which expedites application actions to within 6 months. You can read the full press release here.

 

ABOUT US

© New Kapitall Holdings LLC. All rights reserved. Kapitall Wire is a division of New Kapitall Holdings LLC. Kapitall Generation, LLC is a wholly owned subsidiary of New Kapitall Holdings LLC. Kapitall Wire, which is not a broker/dealer, offers free cutting edge content and commentary and is produced for informational purposes only and should not be construed as research. Kapitall Wire is a product offered by New Kapitall Holdings, however, KapGen compliance personnel will oversee all Kapitall Wire material prior to release.

 

More from Stocks

Market Movers: Tech Earnings

Market Movers: Tech Earnings

Cloud Gaming Adds Growth Opportunity for Microsoft

Cloud Gaming Adds Growth Opportunity for Microsoft

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Throwback Thursday: To Trade or Not to Trade Paypal

Throwback Thursday: To Trade or Not to Trade Paypal

Daimler's Going Autonomous With Nvidia to Take On Uber, Ride-Hailing Race

Daimler's Going Autonomous With Nvidia to Take On Uber, Ride-Hailing Race